germ cell cancer
Conditions
Interventions
Combination chemotherapy with gemcitabine, oxaliplatin and paclitaxel
Sponsors
Department of Urology, Tohoku University Graduate School of Medicine
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1.Patients had to present with histologically confirmed germcell tumors. 2.Refractory was defined as incomplete reduction or elevation of serum tumor marker, or increase in the product of perpendicular diameters for any lesion or the appearance of any new lesions during chemotherapy.Relapse was defined as elevation of serum tumor marker after normalization, or the appearance of any new lesions after disappearance of all evidence of disease. 3. Patients wererequired to have a performance status less than 22 before registration of this study. Additional eligibility criteria included adequate major organ function, defined as a lneutrocyte count of 1000,/mm3, a thrombocyte count of 50,000/mm3, serum creatinine level less than 1.5 times the upper limit of normaland a liver enzyme level less than 2.5 times the upper limit of normal.
Exclusion criteria
Exclusion criteria: 1.patient with symptomatic interstitial pneumonia 2.patient with grade 3 or 4 cardiac insufficiency with NYHA classification 3.patient with severe infection 4.patient with severe comorbidity 5.patient with severe allergy 6.patient with active another malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| median survival time, progression free survival | — |
Countries
Japan
Contacts
Public ContactShigeyuki Yamada
Tohoku University Graduate School of Medicine Department of Urology
Outcome results
None listed